Free shipping on all orders over $ 500

Amuvatinib

Cat. No. M1918

All AbMole products are for research use only, cannot be used for human consumption.

Amuvatinib Structure
Synonym:

MP470; HPK 56

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
1mg USD 40  USD40 In stock
2mg USD 58  USD58 In stock
5mg USD 94  USD94 In stock
10mg USD 148  USD148 In stock
50mg USD 398  USD398 In stock
100mg USD 552  USD552 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Amuvatinib (formerly known as MP470), is a novel receptor tyrosine kinase inhibitor, it has inhibitory effect on prostate cancer in combination with Erlotinib in vitro and in vivo. Amuvaninib (MP470) inhibited RAD51 protein expression and HR. Amuvatinib also inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3, which are frequently dysregulated in variety of tumors. Amuvatinib (MP470) exhibits low microM IC50 in prostate cancer cell lines. When LNCaP were treated with MP470 in combination with Erlotinib, additive effects on both cytotoxicity and induction of apoptosis were observed. Furthermore, the MP470-Erlotinib combination produced 30-65% dose-dependent tumor growth inhibition (TGI) in a LNCaP mouse xenograft model. Amuvatinib (MP470) sensitized cells to IR and MMC, agents that are selectively toxic to HR-deficient cells. Mutant forms of c-Kit are often associated with tumor chemoresistance.

Product Citations
Chemical Information
Molecular Weight 447.51
Formula C23H21N5O3S
CAS Number 850879-09-3
Solubility (25°C) DMSO 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Zhao H, et al. Radiother Oncol. The receptor tyrosine kinase inhibitor amuvatinib (MP470) sensitizes tumor cells to radio- and chemo-therapies in part by inhibiting homologous recombination.

[2] Qi W, et al. BMC Cancer. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Related VEGFR/PDGFR Products
Conbercept

Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc.

SU5208 

SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

VEGFR-IN-1 

VEGFR-IN-1 is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for KDR, Flt-1, c-Kit, EGF-R, and c-Src, respectively.

(Z)-Orantinib

(Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively.

(Rac)-SAR131675 

(Rac)-SAR131675 is the racemate of SAR131675.

  Catalog
Abmole Inhibitor Catalog




Keywords: Amuvatinib, MP470; HPK 56 supplier, VEGFR/PDGFR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.